TC
PROF

T3 Companies’s Profound Medical PROF Stock Holding History

T3 Companies’s Portfolio PROF Stock Details PROF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-20,000
Closed -$6.1K – 222
2026
Q1 		$6.1K Buy
+20,000
New +$138K 0.01% 127

Other funds holding PROF

Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
TIM
Timelo Investment Management Aurora, Ontario, Canada $349M AUM 28.06% 1-Year Est. Return
GA
Gagnon Advisors New York $157M AUM 36.77% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
ZCP
Z3 Capital Partners Richmond, Virginia $476M AUM
LBA
Letko, Brosseau & Associates Montreal, Quebec, Canada $6.77B AUM 38.11% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

T3 Companies's PROF Position: Q2 2026 in Review

T3 Companies reduced its Profound Medical (PROF) stake by 49% in Q2 2026, selling an estimated $359K and leaving 55,000 shares worth $366K. The position accounts for 0.39% of the portfolio, ranked #52.

T3 Companies first reported a position in PROF in Q4 2025 and has held it in 3 quarters since. The position peaked at $702K in Q1 2026. 56 funds tracked by Wall St. Rank hold PROF as of Q2 2026.

  • T3 Companies held 55,000 shares of Profound Medical worth $366K as of Q2 2026.
  • T3 Companies sold 53,340 Profound Medical shares in Q2 2026, an estimated $359K.
  • Profound Medical made up 0.39% of T3 Companies's portfolio in Q2 2026, its #52 holding.
  • T3 Companies first reported a position in Profound Medical in Q4 2025 and has held it in 3 quarters since.
  • T3 Companies's Profound Medical position peaked at $702K in Q1 2026.
  • 56 funds tracked by Wall St. Rank held Profound Medical as of Q2 2026.

Based on T3 Companies's 13F filing for Q2 2026, filed 27 Jul 2026.